Alebund Pharmaceuticals (HKG:9637) said that the first participant has been randomized and dosed in a global phase 2b clinical trial evaluating AP306 for hyperphosphatemia in patients receiving maintenance hemodialysis, according to a Tuesday Hong Kong bourse filing.
The multicenter, randomized, double-blind, placebo-controlled study is being conducted at sites in the U.S. and China and plans to enroll about 168 participants.
Topline results are expected in the first half of 2027, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments